Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
4.320
-0.160 (-3.57%)
At close: Aug 24, 2026, 4:00 PM EDT
4.347
+0.027 (0.63%)
After-hours: Aug 24, 2026, 5:19 PM EDT
Camp4 Therapeutics Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Camp4 Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $9.92. The average 1-year stock price forecast is 129.63% higher than the current stock price, while the lowest is $6.50 (+50.46%) and the highest is $15 (+247.22%).
Price Target: $9.92 (+129.63%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Camp4 Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $7.75 → $8 | Buy | Reiterates | $7.75 → $8 | +85.19% | Aug 14, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $12 → $15 | Buy | Reiterates | $12 → $15 | +247.22% | Aug 14, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $7 | Buy | Maintains | $7 | +62.04% | Aug 14, 2026 |
| William Blair | William Blair | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Aug 14, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Upgrades $9 | Buy | Upgrades | $9 | +108.33% | Jun 23, 2026 |
Financial Forecast
Revenue This Year
7.28M
from 3.50M
Increased by 108.19%
Revenue Next Year
6.07M
from 7.28M
Decreased by -16.63%
EPS This Year
-1.04
from -1.65
EPS Next Year
-0.79
from -1.04
EPS and Forward PE are based on non-GAAP adjusted numbers.